DSDelphine De Smedt

Delphine De Smedt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Delphine De Smedt has a total of 260 co-authors. Here are the top co-authors by number of shared publications:

  • Dirk De Bacquer

    Department of Public Health and Primary Care, Ghent University , Ghent

    14 shared publications
  • Els Clays

    Univ Ghent, Dept Publ Hlth, Ghent, Belgium

    10 shared publications
  • Kornelia Kotseva

    National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland; Imperial College Healthcare NHS Trust, London, UK

    8 shared publications
  • Lieven Annemans

    Department of Public Health, Ghent University, Ghent, Belgium

    8 shared publications
  • David Wood

    National Heart & Lung Institute, Imperial College London, London, UK; National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland

    7 shared publications
  • Guy De Backer

    Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

    7 shared publications

Latest Publications

  • Open Access

    Understanding caregivers’ experiences in healthcare transition of young people with chronic conditions: a qualitative study on formal and informal caregivers

    by Natwarin Janssens, Lisa Van Wilder, Luna Antonino, Sarah Van Den Berghe, Noa Van Der Haeghen, Ann Van Hecke, Kim Van Hoorenbeeck, Karsten Vanden Wyngaert, Lies Vyverman, Eva Goossens, et al.

    ObjectiveThe prevalence of childhood-onset chronic conditions continues to rise, including among adolescents and young adults (AYAs), increasing the need for coordinated transfer and transition from pediatric to adult care. Healthcare transition (HCT) aims to prepare AYAs for independent self-management, yet many face uncertainties and up to 40% experience care discontinuity. Effective HCT requires collaboration among informal and formal caregivers, who acknowledge the need for care improvement but differ in HCT strategies. Few studies integrated both perspectives across prevalent chronic conditions, highlighting the need for multi-perspective evidence to inform comprehensive HCT programs.DesignA qualitative study with a phenomenological approach was applied, using semi-structured and focus group interviews. Study participants were (i) parents of AYAs (14-25 years) diagnosed with asthma, type 1 diabetes, and/or obesity; (ii) pediatric, adult-care and primary care HCPs who were experienced in care delivery of asthma, type 1 diabetes, and/or obesity. Interview data were inductively, thematically analyzed using NVivo.ResultsTwenty-two parents and twenty-seven HCPs participated. HCT elicited a state of ambivalence in both participant groups, with three main themes: (i) an inner conflict of letting go of the AYA, including the hesitation to relinquish responsibilities; (ii) role ambiguity with subthemes (b) the need for acknowledgement and (c) clear role delineation; and (iii) a (dis)harmony between healthcare settings. The application of a structured approach was considered a facilitating factor, while building trust remained challenging.ConclusionCurrent findings show that HCT remains largely AYA-focused, with limited attention to parents and HCPs. Ambivalence emerged between fostering AYA independence and the difficulty for parents and pediatric HCPs of letting go, while gaps in coordination highlight the need for clearer roles and structured support.

  • Assessing quality of life in nursing home residents: a systematic review of measurement tools

    by Candice Gruyaert, Eva Pattyn, Kathleen Leemans, Mieke Deschodt, Delphine De Smedt, Jeroen Trybou

    Background and Objectives: Nursing homes (NHs) are key to supporting older adults’ quality of life (QoL). With many QoL instruments available, selecting an appropriate tool is challenging. This study inventories instruments used with NH residents and examines whether they conceptualize QoL as a multidimensional construct. Research Design and Methods: A systematic review was conducted to identify QoL instruments used in NHs. 5 databases were searched in March 2025 using terms related to “elderly,” “nursing home,” “questionnaire,” “psychometrics,” and “quality of life.” Empirical English- or Dutch-language studies were eligible, with no geographic or date restrictions. Reference and citation searches were added. Quality was assessed using the COSMIN Risk of Bias checklist, and questionnaire characteristics and QoL subdomains were analyzed using a QoL concept map. Results: A total of 15,516 records were identified (MEDLINE n = 4,536; Web of Science n = 4,738; CINAHL n = 1,395; Scopus n = 3,395; and Embase n = 1,452), of which 6,680 duplicates were removed. After screening 8,836 titles and abstracts, 370 full texts were assessed, yielding 28 eligible studies. Most questionnaires were setting-specific, QoL-focused, and designed for self-report. Across all instruments, 157 unique themes were mapped onto 7 QoL dimensions; “context and environment” and “social relationships” were most common, whereas “relationship with staff” and “physical health” were addressed less often. Discussion and Implications: This study provides an overview of conceptual and practical diversity in QoL tools for NH residents. It highlights the absence of a standardized, comprehensive tool tailored to both residents and the NH context.


  • Open Access

    Potentially Clinically Significant Drug-Drug Interactions in Older Adults with Atrial Fibrillation and Multimorbidity: Prevalence, Correlates, and Association with Adverse Clinical Outcomes in a Swedish National Register-Based Study

    by Cheima Amrouch, Davide Liborio Vetrano, Dirk De Bacquer, Nicola Ferri, Ine Simal, Cecilia Damiano, Lu Dai, Amaia Calderón-Larrañaga, Astrid D. H. Brys, Anton De Spiegeleer, et al.

    Purpose Current research on potentially clinically significant drug-drug interactions (DDIs) in individuals with atrial fibrillation (AF) has predominantly focused on DDIs involving direct oral anticoagulants (DOACs), with limited evidence regarding other medications. Our study aimed to: (i) assess the overall prevalence of DDIs; (ii) investigate potential demographic correlates of DDIs; and (iii) examine the association of DDIs with adverse clinical outcomes in a nationwide cohort of older adults with AF and multimorbidity. Methodology Data from the Swedish national registers were linked to establish a cohort with a 2-year follow-up of adults ≥ 65 years who, on 1 January 2017, had a diagnosis of AF, ≥ 1 comorbidity and were prescribed ≥ 2 medications (n = 192,716). This study describes the prevalence of 72 potentially clinically significant DDIs from an adapted explicit international consensus list and a review focused specifically on DDIs involving DOACs. Correlates of DDIs were assessed through logistic regressions. Cox regression analyses were conducted to examine the association between DDIs and adverse clinical outcomes: overall and cardiovascular (CV) mortality, overall and CV hospitalisation, stroke, bleeding, and falls. Results In the overall population, 37.5% presented with ≥ 1 potential DDI, with CV (33.8%) and central nervous system (CNS) drugs (12.4%) most frequently involved. Sex, age, and civil status were most consistently associated with DDIs. Individuals with ≥ 1 DDI had a higher hazard of CV death (hazard ratio 1.28 95% confidence interval (CI) [1.24–1.32]), CV hospitalisation (1.12 [1.10–1.15]) and falls (1.06 [1.02–1.09]). DDIs with DOACs were associated with gastrointestinal bleeding (2.80 [1.35–5.81]). DDIs with CNS drugs were associated with stroke (1.19 [1.09–1.29]) and falls (1.32 [1.27–1.39]). Conclusion Potentially clinically significant DDIs were prevalent in older adults with AF and multimorbidity, with adverse clinical implications. Identifying these high-risk groups is essential for preventive strategies and effective clinical management.


  • Existing health disparities in congenital heart disease: the path forward to achieving health equity—A scientific statement of the European Association of Preventive Cardiology of the ESC

    by Aparna Kulkarni, Eva Goossens, Kira Kuschnerus, Peter Kramer, Delphine De Smedt, Maria Simonenko, Johannes Nordmeyer, Monica Tiberi, Paul Kantor

    There is increasing recognition that social determinants of health affect outcomes in individuals with congenital heart disease and cause health disparities. This scientific statement from the European Association of Preventive Cardiology of the European Society of Cardiology provides an outline of the existing disparities from a global perspective in this population. We review the current knowledge on racial and ethnic patterns and the role of deprivation status, food insecurity, built environment, financial strain, psychological health and parental distress and education and literacy in creating inequities. Finally, we provide future directions for policy, research, and clinical practice in achieving health equity in the congenital heart disease population.


  • Open Access

    Home-based exercise and physical activity intervention after kidney transplantation: impact of exercise intensity (PHOENIX-Kidney). Protocol for a multicentre randomized controlled trial

    by Stefan De Smet, Marieke Vandecruys, Jasmine De Beir, Sofie Leunis, Karsten Vanden Wyngaert, Marie Renier, Henriette de Loor, Kaatje Goetschalckx, Maarten Naesens, Delphine De Smedt, et al.

    Background: Cardiovascular (CV) disease represents a leading cause of death in kidney transplant recipients (KTRs). Poor physical fitness adds to the increased CV risk of KTRs. Exercise-based rehabilitation and physical activity interventions may prove pivotal in both short and long-term outcomes after kidney transplantation. Methods: PHOENIX-Kidney is a prospective, multicentre, randomized, controlled, single-blinded trial with parallel groups. A total of 147 adult de novo KTRs from two independent Belgian transplant centres will be randomized to one of three groups with different exercise intensity: (i) 6 months moderate-intensity aerobic and muscle strengthening exercise training followed by a physical activity intervention (MIT, n = 49), (ii) 6 months moderate- and high-intensity aerobic exercise training and moderate-intensity muscle strengthening exercise training followed by a physical activity intervention (MHIT, n = 49), or (iii) sham exercise training, not followed by a physical activity intervention (CON, n = 49). The training and physical activity interventions are home-based programmes, which will be initiated at 3 and 9 months after transplantation, respectively. Study participants will be followed up until 2 years after transplantation. The primary hypothesis is that peak oxygen uptake (VO2peak) assessed after the 6-month home-based training programme (the primary outcome) will increase more in MHIT than in CON. Secondary hypotheses are that VO2peak will increase more in MIT compared to CON, and more in MHIT compared to MIT. Secondary endpoints encompass changes in 6-minute walking distance, endothelial function (flow-mediated dilation of the arteria brachialis), health-related quality of life, physical activity, and safety. Conclusion: PHOENIX-Kidney is the first adequately powered RCT to address the question of optimal training intensity in KTRs. Moreover, the implementation potential of a home-based exercise programme followed by a physical activity intervention will be formally assessed in a real-world clinical setting. Clinical Trial Registration: Clinicaltrials.gov identifier number: NCT06260579.


  • Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost–benefit analysis

    by Barbara O M Claus, Delphine De Smedt, Pieter A De Cock

    Background: AUC-based dosing with validated Bayesian software is recommended as a good approach to guide bedside vancomycin dosing. Objectives: To compare treatment and vancomycin-associated acute kidney injury (AKI) costs between Bayesian AUC-based dosing and conventional therapeutic drug monitoring (TDM) using steady-state plasma concentrations of vancomycin administered as continuous infusion in hospitalized non-critically ill patients with severe Gram-positive infection. Methods: A cost–benefit analysis presented as a return on investment (ROI) analysis from a hospital perspective was conducted using a decision tree model (TDM versus AUC-based dosing) to simulate treatment cost (personnel, serum sampling and drug cost), vancomycin-associated AKI risk and cost up to 14 days. ROI was calculated against AUC-based software cost. One-way and probabilistic sensitivity analyses (respectively OWSA and PSA) were performed to check for robustness. Results: In base case, an overall cost per patient of €621.0 with TDM and €543.6 with AUC-based dosing resulted in a treatment saving of €77.4 per patient when applying AUC-based dosing. This saving against the software cost (€26.9/patient) generated an ROI per patient of €1.9 per invested € in software [€1.9 (95% CI 1.6–2.2) in PSA]. Enrolling 900 AUC-based dosed patients annually translated to a net saving of €45 469. Software break-even was reached after 313 patients. In OWSA, a higher AKI risk with TDM strongly contributed to a positive ROI. Conclusions: AUC-based dosing appeared a cost-saving strategy compared with conventional TDM when applying base-case settings of vancomycin-associated AKI risk, treatment and AKI costs.


  • Top Cited Papers
    Open Access

    European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics

    by Adam Timmis, Victor Aboyans, Panos Vardas, Nick Townsend, Aleksandra Torbica, Maryam Kavousi, Giuseppe Boriani, Radu Huculeci, Denis Kazakiewicz, Daniel Scherr, et al.

    This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were collected by questionnaire circulated to the national cardiac societies of ESC member countries. Statistics pertaining to 2022, or latest available year, are presented. New material in this report includes contemporary estimates of the economic burden of CVD and mortality statistics for a range of CVD phenotypes. CVD accounts for 11% of the EU’s total healthcare expenditure. It remains the most common cause of death in ESC member countries with over 3 million deaths per year. Proportionately more deaths from CVD occur in middle-income compared with high-income countries in both females (53% vs. 34%) and males (46% vs. 30%). Between 1990 and 2021, median age-standardized mortality rates (ASMRs) for CVD decreased by median >50% in high-income ESC member countries but in middle-income countries the median decrease was <12%. These inequalities between middle- and high-income ESC member countries likely reflect heterogeneous exposures to a range of environmental, socioeconomic, and clinical risk factors. The 2023 survey suggests that treatment factors may also contribute with middle-income countries reporting lower rates per million of percutaneous coronary intervention (1355 vs. 2330), transcatheter aortic valve implantation (4.0 vs. 153.4) and pacemaker implantation (147.0 vs. 831.9) compared with high-income countries. The ESC Atlas 2023 report shows continuing inequalities in the epidemiology and management of CVD between middle-income and high-income ESC member countries. These inequalities are exemplified by the changes in CVD ASMRs during the last 30 years. In the high-income ESC member countries, ASMRs have been in steep decline during this period but in the middle-income countries declines have been very small. There is now an important need for targeted action to reduce the burden of CVD, particularly in those countries where the burden is greatest.


  • Open Access

    A holistic framework for integrated sustainability assessment of pharmaceuticals

    by Lisa Van Wilder, Lieselot Boone, Ad Ragas, Caroline Moermond, Lowik Pieters, Aissa Rechlin, Rodrigo Vidaurre, Delphine De Smedt, Jo Dewulf


  • The impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review

    by Yasmine Khan, Nick Verhaeghe, Brecht Devleesschauwer, Lisa Cavillot, Sylvie Gadeyne, Nele Pauwels, Laura Van Den Borre, Delphine De Smedt

    Aims: Cardiovascular diseases (CVD) are the leading cause of death worldwide. The coronavirus disease 2019 (COVID-19) pandemic has disrupted healthcare systems, causing delays in essential medical services, and potentially impacting CVD treatment. This study aims to estimate the impact of the pandemic on delayed CVD care in Europe by providing a systematic overview of the available evidence. Methods and results: PubMed, Embase, and Web of Science were searched until mid-September 2022 for studies focused on the impact of delayed CVD care due to the pandemic in Europe among adult patients. Outcomes were changes in hospital admissions, mortality rates, delays in seeking medical help after symptom onset, delays in treatment initiation, and change in the number of treatment procedures. We included 132 studies, of which all were observational retrospective. Results were presented in five disease groups: ischaemic heart diseases (IHD), cerebrovascular accidents (CVA), cardiac arrests (CA), heart failures (HF), and others, including broader CVD groups. There were significant decreases in hospital admissions for IHD, CVA, HF and urgent and elective cardiac procedures, and significant increases for CA. Mortality rates were higher for IHD and CVA. Conclusion: The pandemic led to reduced acute CVD hospital admissions and increased mortality rates. Delays in seeking medical help were observed, while urgent and elective cardiac procedures decreased. Adequate resource allocation, clear guidelines on how to handle care during health crises, reduced delays, and healthy lifestyle promotion should be implemented. The long-term impact of pandemics on delayed CVD care, and the health-economic impact of COVID-19 should be further evaluated.


  • Open Access

    Promotion of healthy nutrition in primary and secondary cardiovascular disease prevention: a clinical consensus statement from the European Association of Preventive Cardiology

    by Vassilios S Vassiliou, Vasiliki Tsampasian, Ana Abreu, Donata Kurpas, Elena Cavarretta, Martin O’fLaherty, Zoé Colombet, Monika Siegrist, Delphine De Smedt, Pedro Marques-Vidal

    Background: Poor dietary habits are common and lead to significant morbidity and mortality. However, addressing and improving nutrition in various cardiovascular settings remain sub-optimal. This paper discusses practical approaches to how nutritional counselling and promotion could be undertaken in primary care, cardiac rehabilitation, sports medicine, paediatric cardiology, and public health. Discussion: Nutrition assessment in primary care could improve dietary patterns and use of e-technology is likely to revolutionize this. However, despite technological improvements, the use of smartphone apps to assist with healthier nutrition remains to be thoroughly evaluated. Cardiac rehabilitation programmes should provide individual nutritional plans adapted to the clinical characteristics of the patients and include their families in the dietary management. Nutrition for athletes depends on the sport and the individual and preference should be given to healthy foods, rather than nutritional supplements. Nutritional counselling is also very important in the management of children with familial hypercholesterolaemia and congenital heart disease. Finally, policies taxing unhealthy foods and promoting healthy eating at the population or workplace level could be effective for prevention of cardiovascular diseases. Within each setting, gaps in knowledge are provided. Conclusion: This clinical consensus statement contextualizes the clinician’s role in nutrition management in primary care, cardiac rehabilitation, sports medicine, and public health, providing practical examples of how this could be achieved.